The deconvolution of transcriptomic data from heterogeneous tissues in cancer studies remains challenging. Available software faces difficulties for accurately estimating both componentspecific proportions and expression profiles for individual samples. To address these challenges, we present a new R-implementation pipeline for the more accurate and efficient transcriptome deconvolution of high dimensional data from mixtures of more than two components. The pipeline utilizes the computationally efficient DeMixT R-package with OpenMP and additional cancer-specific biological information to perform three-component deconvolution without requiring data from the immune profiles. It enables a wide application of DeMixT to gene expression datasets available from cancer consortium such as the Cancer Genome Atlas (TCGA) projects, where, other than the mixed tumor samples, a handful of normal samples are profiled in multiple cancer types. We have applied this pipeline to two TCGA datasets in colorectal adenocarcinoma (COAD) and prostate adenocarcinoma (PRAD). In COAD, we found varying distributions of immune proportions across the Consensus Molecular Subtypes, from the highest to the lowest being CMS1, CMS3, CMS4 and CMS2. In PRAD, we found the immune proportions are associated with progression-free survival (p<0.01) and negatively correlated with Gleason scores (p<0.001). Our DeMixT-centered analysis protocol opens up new opportunities to investigate the tumor-stroma-immune microenvironment, by providing both proportions and component-specific expressions, and thus better define the underlying biology of cancer progression. Availability and implementation: An R package, scripts and data are available: https://github.com/wwylab/DeMixTallmaterials.
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Background Solid tumor tissue samples often consist of more than one distinct tissue compartment. For example, the tumor-immune cell contexture has been anatomically demonstrated to primarily consist of a tumor core, lymphocytes and other non-cancerous cells 1, 2 . Thus, cellular heterogeneity adds confounding complexity to genomic analyses in cancer studies, complicating the evaluation of individualized clinical outcomes. Recently, several computational approaches have been proposed to help understand the heterogeneity of tumor tissues. These approaches are rationalized to circumvent the high expense and long time from previous experimental approaches such as laser-capture microdissection (LCM) and cell sorting for deconvolution.
Most commonly available computational methods using high-throughput expression data faces distinct challenges. Some are limited to two distinct components, without consideration of immune cells 3, 4 . Others require knowledge of cell-type-specific gene lists, i.e., reference genes [5] [6] [7] [8] . In addition, some do not account for sample variances within each component, which can result in large biases in the estimated mixing proportions and mean expressions 9 . We recently proposed a statistical modeling framework, DeMixT, for jointly estimating the proportions and component-specific and sample-specific gene expression levels with more than two components 10 .
To perform deconvolution, the DeMixT method requires expression data from p-1 components, where p is either 2 or 3, the total number of components for deconvolution. The Cancer Genome Atlas (TCGA) projects have generated high-throughput RNAseq data in over 11,000 tumor samples across 33 cancer types, among which 16 have data from normal tissue samples.
None of the cancer types in TCGA has data from expression profiles of the actual immune component. Previously, we successfully ran DeMixT 3-component deconvolution on TCGA head-neck squamous cell carcinoma (HNSC) dataset, using biological information such as the human papillomavirus (HPV) status 10 . To overcome the likely persisting issue of lacking immune profiles, we have developed a general analysis pipeline to perform three component deconvolution, i.e., stroma, immune and tumor, using datasets from TCGA or studies of a similar design. Other persisting issues in deconvolution include computational efficiency and accuracy, due to the high dimensional parameter space we are interrogating. Here, we describe top-down, the implementation and results of the new pipeline, from the pipeline setup, to the DeMixT R package with parallel computing, then to a new adaptive numerical integration approach for the core repetitive calculation inside DeMixT.
Implementation
A three-component deconvolution pipeline that requires only reference profiles from the stromal component. This pipeline is applicable to the TCGA datasets where the gene expression data from mixed tumor samples and normal samples are available but no immune profiles are provided. As shown in Figure 1 , we first select a set of tumor samples that are known to be high in tumor content (e.g., DeMixT 2-component proportion > 85%) to obtain the tumor-specific expression profile. We then select a set of tumor samples that are known to be high in immune content (clinically annotated) to use the tumor-specific expression profile and the normal profile to obtain the immune-specific expression profile. This immune profile is then used together with the normal profile and the full set of mixed tumor samples as input data of DeMixT to obtain the final results.
We have developed the corresponding pipelines for colon adenocarcinoma (COAD) and prostate adenocarcinoma (PRAD) in TCGA data with immune indicators, microsatellite instability levels (MSI) 11 , and mutation burden, respectively. The mutation burden for each PRAD sample is calculated based on the TCGA MC3 consensus mutation callers 12 . DeMixT. Our model expresses the observed gene expressions from each gene and each mixed tumor sample as a weighted linear combination of unobserved raw expressions from the components, which each follow a log2-normal distribution and is weighted by its corresponding proportion. The current maximum number of components is three. One component can be assumed unknown, while the distributions of the remaining components need to be estimated from reference samples. DeMixT adopts an approach of iterated conditional modes (ICM) to maximize the full likelihood 13 . We further used a gene-set-based component merging approach (GSCM) to reduce the bias of proportion estimation for three-component deconvolution 10 .
DeMixT R package. A main function
DeMixT is designed to finish the whole pipeline of deconvolution for two or three components. The DeMixT.S1 function is designed for the first The integration triangle region of the full likelihood function for three components are dichotomized into four regions (represented as four colors). We first identify the location of the peak of probability density and then adaptively increase the number of bins near the peak area. An adaptive integration strategy is determined by which region (color) the peak falls into. B,C,D. Three examples of the three-dimensional surface plot of the integral function for each sample and gene. Z axis represents the probability density. The surface in general has a unique peak. The peak in B sits in the red area. The peak in C sits in the blue area. The peak in D sits in the yellow area. ) and $%~( 7,% , 7,% 2 ). For a given gene and sample, the likelihood can be calculated based on the following 10 :
( | 1 , 2 , 51 , 51 , 52 , 52 , 7 , 7 ) = :
Where ( = , > ) is probability density function, = = The triangle in Figure 2A represents domain of ( = , > ) for the probability function ( = , > ), which is shown as a 3-D peak in Figures 2B, 2C and 2D. When ( = , > ) falls in the boundary region of the domain space of ( = , > ), as shown in Figure 2A in yellow, blue and grey, it is peaked (>75% of total peak volume) in a small region. When ( = , > ) are centered, as shown in Figure 2A in red, it is more spread out in that region, justifying for an even grid summation. The regular two-dimensional integration, i.e., rectangle method, starts with dichotomizing the integration domain (triangle) into even size grid (square), then summing up all integration values across all grids. Instead of evenly separating the grids within the integration domain, our new adaptive integration re-distributes more grids (maintaining the same total amount of grids for stable computing time, default at 3,600) near the mode of probability density when it sits inside the boundary area: yellow, blue and grey (Figure 2A) . By doing this, the adaptive integration is able to achieve better accuracy using the same number of grids. Further details of the adaptive integration algorithm are provided in the Supplementary Materials. TCGA Prostate Adenocarcinoma (PRAD) dataset 14 : We generated tumor-stroma-immune proportions for PRAD by selecting tumor samples with tumor purity higher than 85% in a twocomponent deconvolution to create the tumor profile, and then selecting high immune samples guided by mutation burden (total number of mutations) larger than 100 to build the immune profile 15 . Here the mutation burden is calculated based on the consensus mutation calls 12 made on the whole-exome sequencing data generated from the same sample. Across 295 samples, the immune proportions have a median of 29% and a median absolute deviation (MAD) of 16%;
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the tumor proportions have a median of 56% and a MAD of 24%; and stroma proportions have a median of 12% and a MAD of 9% (Figure 3A) . With these proportions available, we compared the immune proportions with clinical annotations of the patients samples. Interestingly, we saw significantly different immune proportions across patients with different Gleason scores (6, 7 and >7, p<0.001, Figure 3C) , with high Gleason scores presenting the lowest immune proportions. Gleason score is a grading system developed by pathologist that is widely used to evaluate the aggressiveness of prostate cancer clinically 16 . Patients graded with higher Gleason scores (>7) have more aggressive tumors. We further divided the patients into two equal-sized groups: high immune (>29%) and low immune (<29%), and found statistically significant differences in progression-free survival (PRS) outcome between the two groups, after adjusting for age and sex (p=0.002, Figure 3D) . PFS is the period between the date of the first cancer diagnosis and the date of a new occurrence of a tumor event. It has been shown to be a good surrogate for cancer specific survival in prostate cancer 17 , given the long latency for prostate cancer and relative limited follow-up time of this more recent clinical cohort. Importantly, patients with high estimated immune proportions had significantly higher progression-free probability than patients with low estimated immune proportions.
TCGA Colorectal Adenocarcinoma (COAD) dataset 18 : Similarly, the tumor-stroma-immune proportions for COAD were generated by selecting high tumor samples with tumor purity higher than 90% (this cutoff is also cancer-type specific), and then selecting samples who were of high microsatellite instability 11 as high immune samples. Out of the 442 patient samples, we observed the median of tumor proportion is 69% with MAD 22%, the median of immune proportion is 15% with MAD 17% and the median of stroma proportion is 11% with MAD 8% (Figure 3B) . In colorectal cancer, recent studies on the consensus molecular subtypes (CMS) classification system have identified four consensus molecular subtypes, termed CMS1-4 19 . The (Figure 2A) . To ensure a fair comparison, we limited the number of bins to ensure the same numbers between regular and adaptive integration, e.g., the total bins were fixed to 3,600 for each sample and gene. We used concordance correlation coefficient (CCC) and Root Mean Squared Error (RMSE) to compare between the estimated 7,% , 7 and true values using the two approaches for the likelihood calculation, respectively. Higher values in CCC (maximum is 1) and lower values in RMSE (minimum is 0) suggest better performances. As shown in Table 1 , both criteria demonstrated a highly improved performance for parameter estimation when we use the adaptive numerical integration. 
Discussion
We present an R implementation of three-component transcriptome deconvolution pipeline that is built on our R package DeMixT_0.2 with more practical requirement for the input data, i.e., Cancer-specific, three-component deconvolution pipelines for other cancer types can be adapted from our general pipeline in a similar fashion. We consulted with and worked closely with physician scientists for reliable and benchmarked biological information in order to perform meaningful deconvolution in prostate and colorectal cancer. We therefore present this pipeline in a general term, expecting substantial biological input and effort to communicate across disciplines for further cancer-specific application, rather than an assumption-based-methodsguided analysis, e.g. using another deconvolution method as pseudo-truth. In our pipeline, we assumed the tumor-profiles derived from samples with high tumor content are representative of those in samples with high immune content. We also assumed that the immune profiles from samples with high immune content are representative across all samples. These assumptions will be further evaluated after we collect more biological information for deconvolution in future study, as it is a mostly unexplored territory. Future versions of the software will consider an extension with a hierarchical model for immune subpopulations that will allow deconvolution for more than three components and include dynamic immune components.
